China
Africa
Explore chapters and articles related to this topic
Cardiovascular Drugs
Published in Radhwan Nidal Al-Zidan, Drugs in Pregnancy, 2020
Risk Summary: The use of Pitavastatin is contraindicated during pregnancy due to the fact that Cholesterol and products synthesized by cholesterol are essential during fetal development. Moreover, the discontinuation of Pitavastatin during pregnancy should have no influence on the long-term treatment of hyperlipidemia.
Impotent drug regulation
Published in Peter C. Gøtzsche, Richard Smith, Drummond Rennie, Deadly Medicines and Organised Crime, 2019
Peter C. Gøtzsche, Richard Smith, Drummond Rennie
We are also told about liver injuries. Liver enzyme tests should be performed before treatment starts and if signs or symptoms of liver injury occur. It seems a bit late to measure liver enzymes if the liver is already injured. ‘There have been rare post-marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including pitavastatin.’ The drug might kill me.
Lopinavir
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Harry W. Lampiris, Catherine A. Koss
The combination with pimozide and cisapride should be avoided because of the potential for cardiac arrhythmia. The use of lopinavir–ritonavir with ergot derivatives can lead to serious peripheral ischemia because of the potent vasocon-stricting effects of this class. Simvastatin and lovastatin are contraindicated because of the risk of myopathy, including rhabdomyolysis. Atorvastatin, pravastatin, and rosuvastatin are possible alternatives if low doses are used and patients are closely monitored. Pitavastatin is an alternative that requires no dose adjustment.
Pitavastatin-loaded bilosomes for oral treatment of hepatocellular carcinoma: a repurposing approach
Published in Drug Delivery, 2022
Maged Kharouba, Amal El-Kamel, Radwa Mehanna, Eman Thabet, Lamia Heikal
Pitavastatin, also known as NK-104, is a lipophilic potent member of the statin family that is widely used for hypercholesterolemia. It is structurally similar to 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA); therefore, it binds and inhibits the enzyme utilized in HMG-CoA formation, HMG-CoA reductase enzyme. Inhibition of HMG-CoA reductase enzyme prevents the formation of mevalonate which is essential for cholesterol production, leading to increased internalization of LDL and more expression of LDL-receptor mRNA. The structure of PIT contributes to its unique superior pharmacological effects compared to other statins. Recently, PIT was repurposed for its anti-cancer activity toward various types of cancer including lung (Hu et al., 2020), pancreatic (Chen et al., 2020), ovarian (De Wolf et al., 2018), breast (Bytautaite and Petrikaite, 2020), and liver cancer (You et al., 2016). Its anti-cancer activity in HCC was not fully understood, but research owes its anti-cancer activity to decreased growth of liver cancer cells, caspase-dependent induction of liver cancer cells apoptosis (You et al., 2016), and inhibition of TNF-alpha induced inflammation in HCC (Wang et al., 2006). Additionally, PIT is considered class II drug according to the Biopharmaceutics Classification System (BCS), and suffers from poor solubility and bioavailability (Ashfaq et al., 2022).
Improvement of endothelial function by pitavastatin: a meta-analysis
Published in Expert Opinion on Pharmacotherapy, 2018
Niki Katsiki, Željko Reiner, Eugenia Tedeschi Reiner, Khalid Al-Rasadi, Matteo Pirro, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Pitavastatin is the latest statin to receive regulatory approval and become available in the European Union, but it is widely prescribed in Asia [13]. Pitavastatin has a half-life of up to 12 h [14]. Its minimal metabolism by cytochrome (CYP) P450 3A4 and CYP2C9 decreases the likelihood of drug–drug interactions [14]. Pitavastatin (2.5 mg/day) may be as potent and safe as the most effective statins, atorvastatin (10 mg/day) and rosuvastatin (2 mg/day) [15]. There are limited data supporting similar LDL-C-lowering effects for pitavastatin 4 mg and atorvastatin 20–40 mg [16]. However, large-scale studies are required to determine whether pitavastatin is superior when compared with some other statins [17]. Pitavastatin also increases high-density lipoprotein-cholesterol (HDL-C) levels and improves HDL function [18–20]. Notably, the pitavastatin-induced HDL-C increase has been associated with a greater atherosclerotic plaque volume reduction than that obtained with other statins [21]. Finally, unlike other statins, pitavastatin may not be associated with an increased risk of new-onset type-2 diabetes mellitus, although not all the evidence is consistent with that conclusion [22,23].
An evaluation of pitavastatin for the treatment of hypercholesterolemia
Published in Expert Opinion on Pharmacotherapy, 2019
Paul Chan, Li Shao, Brian Tomlinson, Yuzhen Zhang, Zhong-Min Liu
This review will summarize the pharmacology and discuss the efficacy, safety, and tolerability of pitavastatin. The materials reviewed were identified by searching PubMed for publications using ‘pitavastatin’ as the primary search term. Articles written in languages other than English were not included. We searched the reference lists of articles identified by this search strategy and selected those considered relevant. We also referred to the manufacturer’s published information about pitavastatin.